Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;31(7-a Suppl):S1-S13.
doi: 10.18553/jmcp.2025.31.7-a.s1.

Mind over migraine: Disease burden, innovative therapies, and managed care trends in treating migraine disease

Affiliations

Mind over migraine: Disease burden, innovative therapies, and managed care trends in treating migraine disease

Bridget Flavin et al. J Manag Care Spec Pharm. 2025 Jul.

Abstract

Migraine is a genetically influenced complex neurological disease characterized by attacks of moderate to severe headaches and a variety of concomitant symptoms. Migraine disease can significantly impact individuals' daily activities and quality of life. It is a major cause of disability and loss of productivity, which can be exacerbated by migraine-related stigma. Recent advances in migraine treatment and ongoing research may offer additional options for patients; however, treatment barriers still exist, resulting in underdiagnosis and undertreatment of migraine disease, especially in some minority and vulnerable groups. Primary care and emergency department providers are often the first point of contact for patients with migraine disease, so there is opportunity for them to assist in addressing these barriers, particularly with strategies to make care more patient-centered. Managed care organizations can also play a role in overcoming these barriers and supporting equitable access.

PubMed Disclaimer

Conflict of interest statement

This supplement was written by Bridget Flavin, PharmD, CMPP, Founder, Connected Content, Ltd. Connected Content, Ltd., received payment from AMCP for the preparation of this manuscript. Flavin is also an adjunct associate professor at the University of Florida College of Pharmacy and reports stock in Elevance Health. AMCP conceptualized this supplement, and funding was provided by an independent medical education grant from Pfizer, Inc. Pfizer, Inc., manufactures Zavzpret (zavegepant) and Nurtec ODT (rimgepant).

Figures

FIGURE 1
FIGURE 1
Phases of Migraine Attack , ,
FIGURE 2
FIGURE 2
Migraine Disease Patient Journey , ,

Similar articles

References

    1. Pescador Ruschel MA, De Jesus O. Migraine Headache. Updated July 5, 2024. In: StatPearls. [Internet] StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK560787/ - PubMed
    1. Chiang CC, Porreca F, Robertson CE, Dodick DW. Potential treatment targets for migraine: Emerging options and future prospects. Lancet Neurol . 2024;23(3):313-24. doi: 10.1016/S1474-4422(24)00003-6 - DOI - PubMed
    1. Khan J, Asoom LIA, Sunni AA, et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother . 2021;139:111557. doi: 10.1016/j.biopha.2021.111557 - DOI - PubMed
    1. Guo S, Jansen-Olesen I, Olesen J, Christensen SL. Role of PACAP in migraine: An alternative to CGRP? Neurobiol Dis . 2023;176:105946. doi: 10.1016/j.nbd.2022.105946 - DOI - PubMed
    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi: 10.1177/0333102417738202 - DOI - PubMed

MeSH terms

LinkOut - more resources